{"id":117543,"date":"2026-09-04T11:34:56","date_gmt":"2026-09-04T11:34:56","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/117543\/"},"modified":"2026-09-04T11:34:56","modified_gmt":"2026-09-04T11:34:56","slug":"gsk-to-advance-mrna-influenza-vaccine-into-phase-iii-development","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/117543\/","title":{"rendered":"GSK to Advance mRNA Influenza Vaccine Into Phase III Development"},"content":{"rendered":"\n

GSK plc\u00a0GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development. <\/p>\n

This advancement is supported by positive results from a phase II study, which showed that the company’s investigational flu vaccine generated higher immune responses compared with standard-dose and high-dose flu vaccines in younger and older adults, respectively. The vaccine was also generally well tolerated. <\/p>\n

Based on these results, the company plans to start a phase III efficacy study on the mRNA-based flu vaccine, which is expected to begin later in September 2026. <\/p>\n

Unlike most existing flu vaccines that primarily target haemagglutinin (“HA”), GSK’s vaccine candidate is designed to target both HA and neuraminidase (“NA”), potentially improving protection against illness and transmission. <\/p>\n

The planned phase III study will be the first study of an mRNA flu vaccine designed to target both HA and NA, per GSK. <\/p>\n

The FDA granted a Fast Track designation to the vaccine candidate for the targeted age indication, reflecting the need for improved flu protection. <\/p>\n

GSK’s Price Performance <\/p>\n

Year to date, GSK stock has increased 6.1% compared with the industry’s 9.7% rise. <\/p>\n

\"Zacks<\/a> Zacks Investment Research <\/p>\n

Image Source: Zacks Investment Research <\/p>\n

GSK’s Competition in the Broader Vaccine Market <\/p>\n

The advancement of the flu vaccine candidate into phase III marks a significant step for GSK’s mRNA vaccine program. Positive phase III data could support further development of the next-generation flu vaccine and potentially broaden GSK’s seasonal influenza vaccine portfolio. <\/p>\n

Despite GSK deciding to advance its mRNA-based seasonal flu vaccine candidate into phase III development, shares of rival vaccine maker Moderna MRNA jumped nearly 10% yesterday following the announcement of the news. <\/p>\n

MRNA probably climbed as investors might have read GSK’s phase III mRNA flu commitment as platform validation rather than a competitive threat to mFlusvia. <\/p>\n

Last month, the FDA approved Moderna’s mRNA-based seasonal influenza vaccine, mFlusiva (mRNA-1010), for adults aged 50 years and older. The approval covers the prevention of influenza disease caused by influenza A and B viruses. <\/p>\n

mFlusiva is expected to be available for the 2026\/2027 U.S. respiratory season. <\/p>\n

GSK’s Zacks Rank & Stocks to Consider <\/p>\n

GSK currently carries a Zacks Rank #3 (Hold). <\/p>\n

Some better-ranked stocks in the biotech sector are Repligen RGEN and\u00a0Anika Therapeutics ANIK, both sporting a Zacks Rank #1 (Strong Buy) at present. You can see\u00a0the complete list of today’s Zacks #1 Rank stocks here. <\/p>\n","protected":false},"excerpt":{"rendered":"GSK plc\u00a0GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development.…\n","protected":false},"author":2,"featured_media":115173,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[45439,47983,20785,47158,14782,47982,47984,30587,8703],"class_list":["post-117543","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-anika-therapeutics","tag-anika-therapeutics-anik","tag-gsk","tag-gsk-plc-sponsored-adr","tag-plc","tag-repligen","tag-repligen-rgen","tag-zacks","tag-zacks-investment-research"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117212566466741917","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/117543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=117543"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/117543\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/115173"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=117543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=117543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=117543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}